Suppr超能文献

在加利福尼亚州中央谷地,关于自愿参与非处方注射器销售的自我报告。

Self-reported participation in voluntary nonprescription syringe sales in California's Central Valley.

作者信息

Pollini Robin A

出版信息

J Am Pharm Assoc (2003). 2017 Nov-Dec;57(6):677-685. doi: 10.1016/j.japh.2017.06.017. Epub 2017 Aug 12.

Abstract

OBJECTIVES

California Senate Bill 41 (SB41), effective January 2012, is a human immunodeficiency virus/hepatitis C virus prevention measure designed to expand syringe access among injection drug users (IDUs) by allowing pharmacies to sell syringes without a prescription. This study assesses self-reported implementation of SB41 and characterizes barriers amenable to intervention.

DESIGN

Interviewer-administered survey.

SETTING AND PARTICIPANTS

Fresno and Kern Counties, CA. Pharmacists and other pharmacy staff (n = 404) at 212 pharmacies.

OUTCOME MEASURE

Self-reported nonprescription pharmacy sales to known or suspected IDUs.

RESULTS

Overall, 29.3% of participants said their pharmacy would sell nonprescription syringes to a known or suspected IDU, whereas a far higher proportion (79.3%) would sell nonprescription syringes to a person with diabetes. More than one-half said that their pharmacy requires nonprescription syringe purchasers to enter their signature and name and address in a log book although that is not required under SB41. Fewer than 2 out of 3 participants (61.1%) knew that it is legal to sell nonprescription syringes to IDUs. That knowledge, as well as having syringe sales practices based on both store policy and discretion, were positively associated with IDU syringe sales after controlling for other factors. Working at an independent pharmacy, agreeing that only people with "medical conditions" such as diabetes should be able to buy syringes, and viewing syringe sales to IDUs as "not good business" were independently but negatively associated with IDU syringe sales.

CONCLUSION

This study complements an earlier syringe purchase trial documenting low participation in voluntary nonprescription syringe sales under SB41 in Fresno and Kern Counties. In the absence of legislation requiring mandatory syringe sales, interventions should be developed to increase knowledge of the law and frame addiction as a medical condition, with a special focus on independent pharmacies. Informational interventions should stress the need to eliminate log book documentation requirements, which may serve as a barrier to IDU purchase.

摘要

目的

加利福尼亚州参议院法案41(SB41)于2012年1月生效,是一项人类免疫缺陷病毒/丙型肝炎病毒预防措施,旨在通过允许药店在无处方的情况下销售注射器,扩大注射吸毒者(IDU)获取注射器的途径。本研究评估了SB41的自我报告实施情况,并确定了适合干预的障碍因素。

设计

访谈员实施的调查。

地点和参与者

加利福尼亚州弗雷斯诺县和克恩县。212家药店的药剂师和其他药房工作人员(n = 404)。

结果指标

自我报告的向已知或疑似注射吸毒者进行非处方药店销售情况。

结果

总体而言,29.3%的参与者表示他们的药店会向已知或疑似注射吸毒者销售非处方注射器,而向糖尿病患者销售非处方注射器的比例要高得多(79.3%)。超过一半的人表示,他们的药店要求非处方注射器购买者在日志簿上签名并填写姓名和地址,尽管SB41并未要求这样做。不到三分之二的参与者(61.1%)知道向注射吸毒者销售非处方注射器是合法的。在控制其他因素后,这种认知以及基于商店政策和自行决定的注射器销售做法与向注射吸毒者销售注射器呈正相关。在独立药店工作、认为只有患有糖尿病等“医疗状况”的人才能购买注射器以及将向注射吸毒者销售注射器视为“不良业务”与向注射吸毒者销售注射器呈独立但负相关。

结论

本研究补充了一项早期注射器购买试验,该试验记录了弗雷斯诺县和克恩县在SB41下自愿非处方注射器销售的参与率较低。在没有强制注射器销售立法的情况下,应制定干预措施,以增加对法律的了解,并将成瘾视为一种医疗状况,特别关注独立药店。信息干预应强调消除日志簿记录要求的必要性,这可能成为注射吸毒者购买的障碍。

相似文献

1
Self-reported participation in voluntary nonprescription syringe sales in California's Central Valley.
J Am Pharm Assoc (2003). 2017 Nov-Dec;57(6):677-685. doi: 10.1016/j.japh.2017.06.017. Epub 2017 Aug 12.
2
Nonprescription syringe sales: a missed opportunity for HIV prevention in California.
J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):31-40. doi: 10.1331/JAPhA.2015.14148.
3
Nonprescription syringe sales: Resistant pharmacists' attitudes and practices.
Drug Alcohol Depend. 2016 Sep 1;166:45-50. doi: 10.1016/j.drugalcdep.2016.06.023. Epub 2016 Jun 27.
4
Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers' practices.
J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S102-10. doi: 10.1097/00042560-199802001-00018.
7
Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007.
J Urban Health. 2010 Jul;87(4):543-52. doi: 10.1007/s11524-010-9483-z.
10
Pharmacists' attitudes and concerns regarding syringe sales to injection drug users in Denver, Colorado.
J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S46-51. doi: 10.1331/1086-5802.42.0.s46.lewis.

引用本文的文献

1
HOME protocol for a national online survey of people who inject drugs.
Harm Reduct J. 2025 Jul 18;22(Suppl 1):125. doi: 10.1186/s12954-025-01260-6.
2
Community pharmacist engagement in HIV and HCV prevention: Current practices and potential for service uptake.
Explor Res Clin Soc Pharm. 2021 Oct 28;4:100088. doi: 10.1016/j.rcsop.2021.100088. eCollection 2021 Dec.
3
Consider the Source: Associations between Syringe Sources and Risky Injection Behaviors in California's Central Valley.
Subst Use Misuse. 2021;56(13):2007-2016. doi: 10.1080/10826084.2021.1963987. Epub 2021 Aug 11.
4
The Role of Pharmacies in the HIV Prevention and Care Continuums: A Systematic Review.
AIDS Behav. 2021 Jun;25(6):1819-1828. doi: 10.1007/s10461-020-03111-w. Epub 2021 Jan 2.
6
Assessing pharmacy-based naloxone access using an innovative purchase trial methodology.
J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):853-860. doi: 10.1016/j.japh.2020.05.016. Epub 2020 Jul 8.
7
Syringe access and health harms: Characterizing "landscapes of antagonism" in California's Central Valley.
Int J Drug Policy. 2020 Jan;75:102594. doi: 10.1016/j.drugpo.2019.10.018. Epub 2019 Nov 24.
8
Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction.
J Am Pharm Assoc (2003). 2019 Nov-Dec;59(6):779-782. doi: 10.1016/j.japh.2019.06.019. Epub 2019 Aug 8.
9
Injection drug use, HIV/HCV, and related services in nonurban areas of the United States: A systematic review.
Drug Alcohol Depend. 2018 Jul 1;188:239-250. doi: 10.1016/j.drugalcdep.2018.03.049. Epub 2018 May 8.
10
Stigma at every turn: Health services experiences among people who inject drugs.
Int J Drug Policy. 2018 Jul;57:104-110. doi: 10.1016/j.drugpo.2018.04.004. Epub 2018 Apr 30.

本文引用的文献

2
County-Level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections Among Persons Who Inject Drugs, United States.
J Acquir Immune Defic Syndr. 2016 Nov 1;73(3):323-331. doi: 10.1097/QAI.0000000000001098.
3
Nonprescription syringe sales: Resistant pharmacists' attitudes and practices.
Drug Alcohol Depend. 2016 Sep 1;166:45-50. doi: 10.1016/j.drugalcdep.2016.06.023. Epub 2016 Jun 27.
5
Nonprescription syringe sales: a missed opportunity for HIV prevention in California.
J Am Pharm Assoc (2003). 2015 Jan-Feb;55(1):31-40. doi: 10.1331/JAPhA.2015.14148.
6
Medical versus fiscal gatekeeping: navigating professional contingencies at the pharmacy counter.
J Law Med Ethics. 2014 Winter;42(4):518-34. doi: 10.1111/jlme.12173.
8
Over-the-counter but out of reach: a pharmacy-based survey of OTC syringe sales in Tijuana, Mexico.
J Health Care Poor Underserved. 2014 May;25(2):637-51. doi: 10.1353/hpu.2014.0090.
9
Community Impact of Pharmacy-Randomized Intervention to Improve Access to Syringes and Services for Injection Drug Users.
Health Educ Behav. 2014 Aug;41(4):397-405. doi: 10.1177/1090198114529131. Epub 2014 Apr 10.
10
Is crime associated with over-the-counter pharmacy syringe sales? Findings from Los Angeles, California.
Int J Drug Policy. 2014 Mar;25(2):244-50. doi: 10.1016/j.drugpo.2013.12.015. Epub 2014 Jan 8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验